Clinical Trials
33 trialsNCT03433183 2026-05-27
SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors
Sarcoma Alliance for Research through Collaboration
Phase 2 Completed
NCT02664935 2026-04-28
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
University of Birmingham
Phase 2 Completed
NCT03213691 2025-02-05
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Completed
NCT01306045 2024-10-01
Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01256359 2024-08-15
DOC-MEK
University of Oxford
Phase 2 Completed
NCT02393690 2024-07-26
Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer
Academic and Community Cancer Research United
Phase 2 Completed
NCT02337530 2024-03-21
Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC
Canadian Cancer Trials Group
Phase 2 Completed
NCT02117167 2024-01-10
SAFIR02_Lung
UNICANCER
Phase 2 Completed
NCT01750281 2023-10-24
SELECT-2
AstraZeneca
Phase 2 Completed
NCT01248247 2022-01-12
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00551070 2020-12-03
Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01222689 2020-07-31
Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01011933 2019-07-23
Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01160718 2019-05-15
Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy
Swiss Cancer Institute
Phase 2 Completed
NCT00890825 2018-06-20
AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients
AstraZeneca
Phase 2 Completed
NCT01143402 2017-07-26
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
National Cancer Institute (NCI)
Phase 2 Completed
NCT01229150 2017-05-23
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00559949 2017-01-30
Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine
National Cancer Institute (NCI)
Phase 2 Completed
NCT00553332 2016-04-22
Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00936221 2016-03-14
Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients
AstraZeneca
Phase 2 Completed
NCT01658943 2016-03-09
S1115
National Cancer Institute (NCI)
Phase 2 Completed
NCT00888134 2016-01-15
Selumetinib in Cancers With BRAF Mutations
National Cancer Institute (NCI)
Phase 2 Completed
NCT01206140 2015-10-05
Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT01333475 2015-09-30
MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01085214 2015-08-19
AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00866177 2015-08-11
MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00588809 2015-08-05
Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00338130 2014-08-13
Randomised Study to Compare the Efficacy of AZD6244 vs TMZ
AstraZeneca
Phase 2 Completed
NCT00372788 2014-08-13
AZD6244 Versus Pemetrexed (Alimta®) in Patients With Non-small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen
AstraZeneca
Phase 2 Completed
NCT00372944 2014-08-13
AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy
AstraZeneca
Phase 2 Completed
NCT00514761 2014-08-13
Phase II Efficacy Study of AZD6244 in Colorectal Cancer
AstraZeneca
Phase 2 Completed
NCT00604721 2014-05-28
Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01116271 2013-01-14
Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With Colorec
AstraZeneca
Phase 2 Completed